Screener
Allogene Therapeutics ALLO Total Operating Expenses
Total Operating Expenses at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $32,003 | $50,200 |
| General and administrative | 14,089 | 14,991 |
| Total operating expenses | 46,092 | 65,191 |
| Loss from operations | (46,092) | (65,191) |
| Other income (expenses), net: | ||
| Interest and other income, net | 3,573 | 5,516 |
| Interest expense | (300) | (150) |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's total operating expenses?
- Allogene Therapeutics (ALLO) reported total operating expenses of $46.09M in Q1 2026.
- How has Allogene Therapeutics's total operating expenses changed year-over-year?
- Allogene Therapeutics's total operating expenses decreased by 29.3% year-over-year, from $65.19M to $46.09M.
- What is the long-term trend for Allogene Therapeutics's total operating expenses?
- Over 4 years (2021 to 2025), Allogene Therapeutics's total operating expenses has grown at a -8.2% compound annual growth rate (CAGR), from $294.28M to $209.32M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Allogene Therapeutics's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude